290 related articles for article (PubMed ID: 11518075)
1. In vitro binding studies with two hypericum perforatum extracts--hyperforin, hypericin and biapigenin--on 5-HT6, 5-HT7, GABA(A)/benzodiazepine, sigma, NPY-Y1/Y2 receptors and dopamine transporters.
Gobbi M; Moia M; Pirona L; Morizzoni P; Mennini T
Pharmacopsychiatry; 2001 Jul; 34 Suppl 1():S45-8. PubMed ID: 11518075
[TBL] [Abstract][Full Text] [Related]
2. Hypericum perforatum L. extract does not inhibit 5-HT transporter in rat brain cortex.
Gobbi M; Valle FD; Ciapparelli C; Diomede L; Morazzoni P; Verotta L; Caccia S; Cervo L; Mennini T
Naunyn Schmiedebergs Arch Pharmacol; 1999 Sep; 360(3):262-9. PubMed ID: 10543427
[TBL] [Abstract][Full Text] [Related]
3. Step by step removal of hyperforin and hypericin: activity profile of different Hypericum preparations in behavioral models.
Butterweck V; Christoffel V; Nahrstedt A; Petereit F; Spengler B; Winterhoff H
Life Sci; 2003 Jun; 73(5):627-39. PubMed ID: 12770617
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression.
Obach RS
J Pharmacol Exp Ther; 2000 Jul; 294(1):88-95. PubMed ID: 10871299
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of benzodiazepine binding in vitro by amentoflavone, a constituent of various species of Hypericum.
Baureithel KH; Büter KB; Engesser A; Burkard W; Schaffner W
Pharm Acta Helv; 1997 Jun; 72(3):153-7. PubMed ID: 9204773
[TBL] [Abstract][Full Text] [Related]
6. Neurochemical studies with St. John's wort in vitro.
Simmen U; Higelin J; Berger-Büter K; Schaffner W; Lundstrom K
Pharmacopsychiatry; 2001 Jul; 34 Suppl 1():S137-42. PubMed ID: 11518063
[TBL] [Abstract][Full Text] [Related]
7. Hyperforin as a possible antidepressant component of hypericum extracts.
Chatterjee SS; Bhattacharya SK; Wonnemann M; Singer A; Müller WE
Life Sci; 1998; 63(6):499-510. PubMed ID: 9718074
[TBL] [Abstract][Full Text] [Related]
8. Researching the antidepressant actions of Hypericum perforatum (St. John's wort) in animals and man.
Franklin M; Cowen PJ
Pharmacopsychiatry; 2001 Jul; 34 Suppl 1():S29-37. PubMed ID: 11518072
[TBL] [Abstract][Full Text] [Related]
9. Hypericum perforatum: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients.
Wurglics M; Schubert-Zsilavecz M
Clin Pharmacokinet; 2006; 45(5):449-68. PubMed ID: 16640452
[TBL] [Abstract][Full Text] [Related]
10. [Cellular and molecular effects of the antidepressant hyperforin on brain cells: Review of the literature].
Bouron A; Lorrain E
Encephale; 2014 Apr; 40(2):108-13. PubMed ID: 23816060
[TBL] [Abstract][Full Text] [Related]
11. Screen of receptor and uptake-site activity of hypericin component of St. John's wort reveals sigma receptor binding.
Raffa RB
Life Sci; 1998; 62(16):PL265-70. PubMed ID: 9585174
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of synaptosomal uptake inhibition of most relevant constituents of St. John's wort.
Wonnemann M; Singer A; Siebert B; Müller WE
Pharmacopsychiatry; 2001 Jul; 34 Suppl 1():S148-51. PubMed ID: 11518066
[TBL] [Abstract][Full Text] [Related]
13. [Hypericin and hyperforin: bioactive components of St. John's Wort (Hypericum perforatum). Their isolation, analysis and study of physiological effect].
Vacek J; Klejdus B; Kubán V
Ceska Slov Farm; 2007 Apr; 56(2):62-6. PubMed ID: 17619301
[TBL] [Abstract][Full Text] [Related]
14. Hyperforin a constituent of St John's wort (Hypericum perforatum L.) extract induces apoptosis by triggering activation of caspases and with hypericin synergistically exerts cytotoxicity towards human malignant cell lines.
Hostanska K; Reichling J; Bommer S; Weber M; Saller R
Eur J Pharm Biopharm; 2003 Jul; 56(1):121-32. PubMed ID: 12837490
[TBL] [Abstract][Full Text] [Related]
15. Extracts of St. John's wort and various constituents affect beta-adrenergic binding in rat frontal cortex.
Simbrey K; Winterhoff H; Butterweck V
Life Sci; 2004 Jan; 74(8):1027-38. PubMed ID: 14672758
[TBL] [Abstract][Full Text] [Related]
16. In vitro photochemical and phototoxicological characterization of major constituents in St. John's Wort (Hypericum perforatum) extracts.
Onoue S; Seto Y; Ochi M; Inoue R; Ito H; Hatano T; Yamada S
Phytochemistry; 2011 Oct; 72(14-15):1814-20. PubMed ID: 21782201
[TBL] [Abstract][Full Text] [Related]
17. Effects of the antidepressant St. John's wort (Hypericum perforatum) on rat and human vas deferens contractility.
Capasso R; Borrelli F; Montanaro V; Altieri V; Capasso F; Izzo AA
J Urol; 2005 Jun; 173(6):2194-7. PubMed ID: 15879886
[TBL] [Abstract][Full Text] [Related]
18. In vitro receptor screening of pure constituents of St. John's wort reveals novel interactions with a number of GPCRs.
Butterweck V; Nahrstedt A; Evans J; Hufeisen S; Rauser L; Savage J; Popadak B; Ernsberger P; Roth BL
Psychopharmacology (Berl); 2002 Jul; 162(2):193-202. PubMed ID: 12110997
[TBL] [Abstract][Full Text] [Related]
19. Effects of a methanolic extract and a hyperforin-enriched CO2 extract of St. John's Wort (Hypericum perforatum) on intracerebral field potentials in the freely moving rat (Tele-Stereo-EEG).
Dimpfel W; Schober F; Mannel M
Pharmacopsychiatry; 1998 Jun; 31 Suppl 1():30-5. PubMed ID: 9684945
[TBL] [Abstract][Full Text] [Related]
20. Study of dynamic accumulation of secondary metabolites in three subspecies of Hypericum perforatum.
Filippini R; Piovan A; Borsarini A; Caniato R
Fitoterapia; 2010 Mar; 81(2):115-9. PubMed ID: 19686808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
